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Little data are available on the relative merits of chimerism and minimal residual disease (MRD) monitoring
for relapse prediction after allogeneic hematopoietic stem cell transplantation (HCT). We performed a
retrospective analysis of serial chimerism assessments in 101 adult HCT recipients with acute lymphoblastic
leukemia (ALL) and of serial MRD assessments in a subgroup of 22 patients. All patients had received mye-
loablative conditioning. The cumulative incidence of relapse was signiﬁcantly higher in the patients with
increasing mixed chimerism (in-MC) compared with those with complete chimerism, low-level MC, and
decreasing MC, but the sensitivity of in-MC detection with regard to relapse prediction was only modest. In
contrast, MRD assessment was highly sensitive and speciﬁc. Patients with MRD positivity after HCT had the
highest incidence of relapse among all prognostic groups analyzed. The median time from MRD positivity to
relapse was longer than the median time from detection of in-MC, but in some cases in-MC preceded MRD
positivity. We conclude that MRD assessment is a powerful prognostic tool that should be included in the
routine post-transplantation monitoring of patients with ALL, but chimerism analysis may provide additional
information in some cases. Integration of these tools and clinical judgment should allow optimal decision
making with regard to post-transplantation therapeutic interventions.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION when the leukemia burden is still low may be effective [7,8].
Allogeneic hematopoietic stem cell transplantation (HCT)
is a well-established postremission therapy in adults with
acute lymphoblastic leukemia (ALL) with certain high-risk
features [1,2]. Some protocols advocate HCT even in standard-
risk ALL [3,4]. HCT is also applied in patients in second or
higher complete remission (CR), and for selected patients
with refractory disease. Although treatment-related mor-
tality has declined in recent years, relapse remains a frequent
cause of death after HCT, particularly in patients with ad-
vanced disease [5].
Salvage therapies for overt hematologic relapse after
HCT are often futile [6], but intervention in early relapseedgments on page 1528.
requests: Dr T.H. Terwey, Department
umor Immunology, CharitéeUniversity
Klinikum, Augustenburger Platz 1, 13353
harite.de (T.H. Terwey).
2014 American Society for Blood and Marrow
14.05.026The 2 methods available for early relapse prediction are
monitoring of minimal residual disease (MRD), by ﬂow
cytometry for leukemia-associated aberrant immunophe-
notypes or by real-time quantitative polymerase chain re-
action (qPCR) for fusion genes or clonal immunoglobulin
or T cell receptor (Ig/TCR) gene rearrangements [9-17], or
sequential measurements of donor chimerism, primarily
by ﬂuorescence-based PCR ampliﬁcation of short tandem
repeat (STR) markers [18-22]. Whereas MRD directly detects
residual or reemerging leukemia clones, chimerism analysis
provides information only on the persistence or reemer-
gence of autologous hematopoiesis. In addition, standard
MRD assays usually have at least a 1 log greater sensitivity
than assays used for the assessment of chimerism [18,23].
Both of these methods have been applied in the post-
transplantation setting in adults with ALL [19], but their
relative merits with regard to relapse prediction have
not been thoroughly evaluated. The impact of chimerism
has been analyzed primarily in pediatric ALL populationsTransplantation.
Table 1
Patient and Treatment Characteristics
Characteristic Value
Number of patients 101
Sex, %
Male 64
Female 36
Age at HCT, yr, median (range) 33 (17-55)
Karnofsky Performance Status, %
100 49
90 41
80 10
HCT-CI, %
Low 28
Intermediate 46
High 27
Disease status at HCT, %
CR1 58
CR2 or greater 19
No CR 23
Lineage, %
B-ALL 71
T-ALL 29
Cytogenetic risk group, %
Philadelphia chromosome positive 22
High risk [t(4;11), t(8;14), CA] 16
Other aberrations 16
Normal karyotype 47
Donor type, %
Matched related donor 37
Matched unrelated donor 51
Mismatched donor 12
Stem cell source, %
Peripheral blood stem cells 91
Bone marrow 9
ATG during conditioning, %
Yes 29
No 71
DLI given, %
Yes 38
No 62
CA indicates complex aberrant.
Percentages may not total 100% because of rounding.
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may exist [28]. MRD studies, although indicating an increased
relapse risk in patients with MRD positivity after HCT
[7,11,29-33], generally have not provided comparative data to
chimerism. In this context, a recent National Cancer Institute
workshop concluded that it is critically important to assess
the clinical relevance of MRD and chimerism surveillance
in individual diseases [19], and a recent evidence-based re-
view on the role of HCT in adult ALL concluded that moni-
toring ofMRD after allogeneic HCT is an areameriting further
research [34].
Here we present a retrospective analysis of serial chime-
rism assessments in 101 adults with ALL, and of serial MRD
assessments in a subgroup of 22 patients, all of whom had
undergone myeloablative allogeneic HCT at our center be-
tween 1999 and 2009. We examined the kinetics of MRD
and chimerism signals and evaluated whether either of
these 2 methods provides better relapse prediction, poten-
tially allowing for earlier and more successful therapeutic
intervention.
PATIENTS AND METHODS
Patients
A total of 146 adults with ALL underwent allogeneic HCT at our center
between 1999 and 2009. For the present study, patients who received
reduced-intensity conditioning and/or underwent a second allogeneic HCT
(n ¼ 31), as well as patients for whom chimerism data were unavailable
(owing to, eg, death before day 28 or follow-up at external centers [n ¼ 14]),
were excluded, leaving a ﬁnal study population of 101 patients (Table 1).
MRD data were available for a subgroup of 22 patients.
All patients were diagnosed and treated under the German Multicenter
Study Group for Adult ALL (GMALL) study protocol 06/99 or 07/03 [1,35,36].
Patient-, disease-, and transplantation-related characteristics and follow-up
information were recorded prospectively in an electronic database, and
chimerism and MRD data, as well as data on the occurrence of graft-versus-
host disease (GVHD), were gathered retrospectively from patient ﬁles by
standardizedmedical record abstraction. All patients gave informed consent
for analysis of their data, in accordance with the Declaration of Helsinki.
The patients were at high risk for relapse or progression and underwent
transplantation in ﬁrst CR (n¼ 59), in second CR or greater (n¼ 19), in active
relapse (n ¼ 21), or with primary refractory disease (n ¼ 2) (Table 1).
Conditioning and GVHD Prophylaxis
Patients received myeloablative conditioning based on total body irra-
diation (TBI) 6  2 Gy, in combination with either cyclophosphamide
2  60 mg/kg (n ¼ 60) or etoposide 1  60 mg/kg (n ¼ 33), cyclophospha-
mide 2  50 mg/kg þ etoposide 1  50 mg/kg (n ¼ 5), or an alternative
regimen without TBI based on treosulfan 3  12 g/m2 þ cyclophosphamide
2  60 mg/kg þ etoposide 1  30 mg/kg (n ¼ 2) or busulfan 4  4 mg/kg þ
cyclophosphamide 2  60 mg/kg (Table 1). GVHD prophylaxis consisted of
cyclosporine A (CSA) combined with short-course methotrexate (n ¼ 76),
mycophenolate mofetil (n ¼ 9), or prednisolone (n ¼ 16). Antithymocyte
globulin (ATG; Fresenius) 3  10 or 20 mg/kg/day was given initially only to
patients withmismatched donors and then, starting in 2004, also in patients
with a matched unrelated donor (n ¼ 29).
Allogeneic Transplantation
HLA typing was performed by PCR sequence-speciﬁc primer low-
resolution typing for HLA class I and genomic high-resolution DNA-based
typing for HLA class II. Stem cell source was either bone marrow (n ¼ 9) or
peripheral blood stem cells (n ¼ 92) from HLA-matched related donors
(n ¼ 37), HLA-matched unrelated donors (n ¼ 52), or HLA-mismatched
donors (n ¼ 12) (Table 1). Leukocyte engraftment was deﬁned as the ﬁrst
of 3 consecutive days with a leukocyte count >1000 mL and/or a neutrophil
count>500 mL. Platelet engraftment was deﬁned as the ﬁrst of 3 consecutive
days with a platelet count >20,000 mL without transfusions. Acute GVHD
(aGVHD), late aGVHD, and chronic GVHD (cGVHD) were classiﬁed according
to the National Institutes of Health consensus criteria [37], as described
previously [38].
Donor Lymphocyte Infusion
Donor lymphocyte infusion (DLI) were administered to 38 patients ac-
cording to a standard protocol [38,39] in a preemptive manner for patients
with persistent or recurrent mixed chimerism (n ¼ 16) or MRD (n ¼ 2), in aprophylactic manner for patients with active disease at transplantation
(n ¼ 13), or in a therapeutic manner for morphological relapse after salvage
chemotherapy (n ¼ 7). DLI was given at 4-week intervals in escalating doses
(related donor: 1  107, 5  107, and 1  108 CD3þ cells/kg body weight;
unrelated donor: 5  106, 1  107, 5  107, and 1  108 CD3þ cells/kg body
weight) after previous discontinuation of immunosuppression and only in
the absence of GVHD and infection.
Chimerism and MRD Analysis
Chimerism analysis was performed at the Institute of Legal Medicine
and Forensic Sciences, CharitéeUniversity Medicine Berlin, and determined
by a multiplex STR assay with 9 STR systems plus the amelogenin gene with
ﬂuorescence-based detection. The analysis included CD4þ, CD8þ, and CD19þ
cells in peripheral blood and CD34þ cells in bone marrow, at a sensitivity
of 102 [40]. Chimerism analysis was performed routinely at 1, 3, 6, 9, 12, 18,
24, 36, 48, and 60 months after transplantation. Patients with no signal of
host DNA during follow-up were categorized as having complete donor
chimerism (CC), whereas patients with a measurable host signal but not
more than 5% at any time point were categorized as low-level mixed
chimerism (ll-MC). Patients with a5% increase in autologous cells between
2 consecutive assessments were classiﬁed as having increasing mixed
chimerism (in-MC), whereas patients with a host signal immediately post-
transplantation that decreased spontaneously were categorized as having
decreasing mixed chimerism (de-MC) [20].
MRD analysis was performed at the GMALL study group central MRD
laboratories, as described in detail elsewhere [16,35,41,42]. In brief, for BCR-
ABLepositive ALL, complementary DNA was synthesized from RNA and
BCR-ABL qPCR was performed, using ABL as the housekeeping gene [42]. For
BCR-ABLenegative ALL, clonal Ig/TCR gene rearrangements were identiﬁed
by gene scanning and/or heteroduplex gel analysis and then sequenced.
MRD was then determined by clone-speciﬁc qPCR, with the aim of using
2 molecular markers with a sensitivity of at least 104. MRD relapse was
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after previous achievement of MRD negativity [16,35,41]. MRD assessments
were done in bone marrow and scheduled for the same intervals as
chimerism analysis.
Statistics
Overall survival (OS) was estimated by the Kaplan-Meier method and
compared using the log-rank test. The cumulative incidences of relapse and
nonrelapse mortality (NRM) were estimated taking into account competing
risks and compared using Gray’s test. The prognostic impact of chimerism
and MRD on relapse, NRM, and OS was estimated using multivariate Cox
proportional hazards regression analysis, with chimerism and MRD status
introduced as a time-dependent covariate [43], in addition to the baseline
characteristics of year of transplantation, sex, age, Karnofsky Performance
Status score, HCT-speciﬁc comorbidity index (HCT-CI), disease status, line-
age, cytogenetic risk group, donor type, stem cell source, use of ATG, and the
time-dependent covariates administration of DLI and occurrence of aGVHD,
late aGVHD, and cGVHD. Sensitivity and speciﬁcity of chimerism and MRD
assessment with regard to relapse detection were assessed as well. Results
of comparative tests were considered signiﬁcant at a 2-sided P value < .05.
Statistical analyses were performed using SPSS 20.0 (IBM, Armonk, NY),
NCSS 9 (NCSS, Kaysville, UT), and the cmprsk package in R (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
Overall Outcome
Leukocyte engraftment occurred a median of 16 days
post-transplantation (range, 10 to 32 days), and platelet
engraftment occurred at a median of 19 days (range, 9 to
82 days). After a median follow-up in surviving patients of
74 months (range, 13 to 140 months), projected OS was 83%
(95% conﬁdence interval [CI], 76% to 90%) at 1 year, 67% (95%
CI, 58% to 76%) at 2 years, 60% (95% CI, 50% to 70%) at 3 years,
and 56% (95% CI, 47% to 66%) at 5 years. The cumulative
incidence of relapse was 20% (95% CI, 13% to 29%) at 1 year,
23% (95% CI, 16% to 33%) at 2 years, 26% (95% CI, 19% to 36%)
at 3 years, and 27% (95% CI, 20% to 37%) at 5 years. Twenty of
29 relapse events (69%) occurred during the ﬁrst year after
transplantation, 4 of 29 events (14%) occurred during the
second year, 3 of 29 events (10%) occurred during the third
year, and 1 event each occurred in years 4 and 8. The median
time to relapse was 6 months (range, 2 to 89 months). NRM
was 12% (95% CI, 7% to 20%) at 1 year, 16% (95% CI, 10% to 25%)
at 2 years,18% (95% CI,12% to 27%) at 3 years, and 18% (95% CI,
12% to 27%) at 5 years. Speciﬁc causes of NRM included GVHD
(n ¼ 14), infection (n ¼ 4), and toxicity (n ¼ 2).
Classiﬁcation of Chimerism Status
The median number of chimerism assessments per pa-
tient was 6 for peripheral blood and 5 for bonemarrow.With
regard to CD4þ cells in peripheral blood, 49% of the 101
analyzed patients had CC,11% had ll-MC, 21% had de-MC, and
19% had in-MC. Classiﬁcation of chimerism status in the
CD8þ and CD19þ cell populations was comparable (CD8þ
cells: 42% CC, 17% ll-MC, 24% de-MC, and 17% in-MC; CD19þ
cells: 47% CC, 14% ll-MC, 22% de-MC, 17% in-MC). In contrast,
classiﬁcation of chimerism status for CD34þ cells in the bone
marrow showed marked differences, with a lower frequency
for CC and a higher frequency for de-MC and in-MC (6% CC,
18% ll-MC, 32% de-MC, and 44% in-MC).
Prognostic Impact of Chimerism Status in Peripheral
Blood
The cumulative incidence of relapse with regard to
chimerism status in peripheral blood CD4þ cells was similar
in patients with CC, ll-MC, and de-MC (22% [95% CI, 12% to
43%], 31% [95% CI, 12% to 83%], and 26% [95% CI, 12% to 55%],
respectively), but signiﬁcantly higher for patients with in-MC(63%; 95% CI, 45% to 89%; P ¼ .00072) (Figure 1A). In-MC
chimerism status also was a negative prognostic factor for
OS, whereas NRM was not signiﬁcantly increased (Figure 1B
and C). In-MC chimerism status remained an independent
negative prognostic factor for relapse and OS when analyzed
in multivariate Cox regression models that included chime-
rism status as a time-dependent covariate, in addition to
baseline patient and transplantation characteristics as well
as the time-dependent covariates administration of DLI and
occurrence of aGVHD, late aGVHD, and cGVHD (Table 2).
Results for relapse, NRM, and OS with regard to chime-
rism status in peripheral blood CD8þ and CD19þ cells were
comparable to the results for CD4þ cells, with the exception
of ll-MC in CD8þ cells, which was identiﬁed as a negative
prognostic factor for NRM (Table 2). Importantly, the prog-
nostic impact of chimerism in the CD4þ, CD8þ, and CD19þ
subpopulations did not change signiﬁcantlywhen chimerism
status was analyzed separately for patients with B-ALL and
those with T-ALL (data not shown).
Prognostic Impact of Chimerism Status in Bone Marrow
The cumulative incidence of relapse with regard to
chimerism status in bone marrow CD34þ cells was similar
in patients with CC, ll-MC, and de-MC (17% [95% CI, 3% to
99%], 17% [95% CI, 6% to 47%], and 14% [95% CI, 4% to 44%],
respectively), but signiﬁcantly higher in patients with in-MC
(53%; 95% CI, 38% to 73%; P ¼ .0016) (Figure 1D). In-MC
chimerism status of CD34þ cells also was identiﬁed as a
negative prognostic factor for OS, whereas NRM was not
increased signiﬁcantly (Figure 1E and F). In-MC chimerism
status of CD34þ cells remained an independent negative
prognostic factor for relapse and OS in multivariate Cox
regression analysis (Table 2).
In patients who relapsed, the median time to relapse after
detection of in-MC in CD34þ bone marrow cells was 116 days
(range, 0 to 2639 days), which trended to be longer com-
pared with 25 days (range, 0 to 641 days) for detection of
in-MC in any of the peripheral blood cell populations
(P¼ .091). In addition, the sensitivity for relapse detection by
identiﬁcation of in-MC status in bonemarrowwas somewhat
higher compared with blood (79% [95% CI, 60% to 90%] versus
55% [95% CI, 37% to 72%]; P¼ .061), whereas the speciﬁcity of
chimerism assessment in bone marrow was signiﬁcantly
lower (70% [95% CI, 58% to 77%] versus 87% [95% CI, 78% to
93%]; P ¼ .012).
Prognostic Impact of MRD Status in Bone Marrow
Serial pretransplantation and post-transplantation qPCR
MRD data were available for a subgroup of 22 patients, of
whom 2 were monitored for BCR-ABL and 20 were moni-
tored for Ig/TCR gene rearrangements. The median number
of MRD assessments per patient was 5, comparable to the
number of assessments for chimerism in peripheral blood
and bone marrow.
With regard to MRD status before transplantation, 8 of
22 patients were MRD-negative, and the other 14 were
MRD-positive. After transplantation, 2 of the 8 patients
who were initially MRD-negative changed to MRD-positive,
whereas 12 of the 14 initially MRD-positive patients ach-
ieved at least temporary MRD negativity.
With regard to the predictive value of MRD after trans-
plantation, 7 of the 22 patients experienced MRD relapse
or MRD persistence after transplantation, whereas the other
15 patients became and/or remained MRD-negative. The
cumulative incidence of hematologic relapse in patients with
Figure 1. (A-C) Cumulative incidence of relapse (A), NRM (B), and OS (C) according to chimerism status in CD4þ peripheral blood T cells in 101 patients undergoing
HCT for ALL. (D-F) Cumulative incidence of relapse (D), NRM (E), and OS (F) according to chimerism status in CD34þ bone marrow cells in these 101 patients.
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only 7% (95% CI, 1% to 44%) in patients who remained MRD-
negative (P ¼ .0035) (Figure 2A).
Post-transplantation MRD relapse also was prognostic for
OS, but not for NRM (Figure 2B and C), and it remained an
independent prognostic factor for relapse and OS when
analyzed in a multivariate Cox regression model with MRD
status as a time-dependent covariate (Table 2).
The median time to hematologic relapse after detection
of MRD relapse was 173 days (range, 0 to 2373 days),
somewhat longer than the interval reported for chimerism.
MRD assessment detected relapse with high sensitivity
(86%; 95% CI, 49% to 97%) and high speciﬁcity (95%; 95% CI,
70% to 99%), comparing favorably with the respective values
for chimerism.
With regard to the prognostic impact of chimerism
assessment in the subgroup of patients with available MRD
data, 4 of the 7 patients with MRD relapse and subsequent
hematologic relapse also would have been detected via a
signal of in-MC, with 3 of these detections occurring earlier
than MRD, but the other 3 patients would have been missed
by relying on the in-MC signal only. Among the 14 patients
without MRD relapse and without hematologic relapse, 9 pa-
tients also would have been negative for in-MC, but the other
5 patients would have generated a false-positive in-MC signal.Extramedullary Relapse
Among the overall 29 cases of relapse, 3 patients had
isolated extramedullary relapse, and 6 patients had com-
bined extramedullary and bone marrow relapse. Two of the
3 patients with isolated extramedullary relapse had an
in-MC signal in bone marrow and blood before relapse,
whereas the other patient had an in-MC signal in blood only.
None of these 3 patients had available MRD data, and thus
we could not evaluate whether MRD would have been pre-
dictive as well. One of the 6 patients with combined extra-
medullary and bone marrow relapse had an in-MC signal in
bone marrow and blood before relapse, whereas the other
5 patients had an in-MC signal in bone marrow only. Thus,
based on this limited experience, chimerism analysis in bone
marrow was able to predict relapse in 8 of 9 cases of extra-
medullary relapse (89% sensitivity), whereas chimerism
analysis in blood was able to predict relapse in only 4 of
9 cases (44% sensitivity), and chimerism analysis in bone
marrow or blood was able to predict relapse in 9 of 9 cases
(100% sensitivity).
Impact of DLI on Chimerism and MRD
Sixteen patients had received preemptive DLI for MC, and
12 of these 16 patients converted to CC after DLI. At last
follow-up, 10 patients in this cohort remained alive in CR.
Table 2
Multivariate Cox Proportional Hazard Regression Analysis Estimating the Effect of Chimerism and MRD Status on Relapse, NRM, and OS
Relapse NRM OS
HR (95% CI) P HR (95% CI) P HR (95% CI) P
CD4þ blood
CC 1 1 1
ll-MC 1.71 (0.46-6.36) .42 3.68 (0.82-16.40) .088 2.49 (0.88-7.01) .085
de-MC 0.84 (0.25-2.81) .78 0.24 (0.03-1.88) .17 0.51 (0.19-1.37) .18
in-MC 5.32 (2.10-13.45) <.001 4.61 (0.91-14.88) .063 4.17 (2.05-8.51) <.001
CD8þ blood
CC 1 1 1
ll-MC 0.91 (0.25-3.33) .89 4.24 (1.35-13.37) .014 2.14 (0.99-4.63) .053
de-MC 0.46 (0.14-1.53) .21 0.19 (0.02-1.49) .113 0.444 (0.16-1.21) .11
in-MC 4.15 (1.64-10.51) .003 3.38 (0.84-13.67) .087 4.19 (1.99-8.86) <.001
CD19þ blood
CC 1 1 1
ll-MC 0.61 (0.17-2.25) .46 0.85 (0.18-4.03) .84 0.96 (0.35-2.62) .93
de-MC 0.52 (0.17-1.61) .25 0.18 (0.02-1.43) .11 0.53 (0.20-1.44) .21
in-MC 4.10 (1.55-10.80) .004 5.13 (0.96-27.37) .056 3.65 (1.71-7.81) .001
CD34þ bone marrow
CC 1 1 1
ll-MC 1.14 (0.26-4.98) .86 2.72 (0.23-31.62) .42 3.07 (0.58-16.31) .19
de-MC 0.46 (0.11-1.98) .29 3.90 (0.46-33.43) .21 3.22 (0.68-15.24) .14
in-MC 3.58 (1.26-10.191) .017 7.03 (0.86-57.63) .069 8.99 (2.11-38.31) .003
MRD bone marrow
Negative 1 1 1
Relapse 24.64 (1.58-384.19) .022 0.04 (0-13074423) .75 9.67 (1.93-48.50) .006
HR indicates hazard ratio.
Prognostic variables examined were transplant year, sex, age, Karnofsky Performance Status, HCT-CI, disease status, lineage, cytogenetic risk group, donor
type, stem cell source, ATG infusion, and the time-dependent covariates application of DLI, occurrence of aGVHD, late aGVHD, and cGVHD, chimerism status,
and MRD status. Only results for chimerism and MRD status are shown here. Other variables with signiﬁcant prognostic impact in the multivariate setting
were disease status and occurrence of cGVHD for relapse and OS and HCT-CI for NRM. HR and P values refer to the comparison of the respective category with
the ﬁrst one.
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or persistent MRD, and both returned to molecular nega-
tivity after DLI. These patients experienced a prolonged
relapse-free interval after DLI but still sustained late relapse,
and both died from leukemia (at 1764 days and 2322 days
after DLI).
Thirteen patients had received prophylactic DLI because
of active disease at time of transplantation; 3 of these pa-
tients had MC at the time of DLI, 1 of whom converted to CC
after DLI. At last follow-up, 8 patients in this cohort remained
alive in CR.
Seven patients were treated with DLI for overt relapse
after receiving additional reinduction therapy. All 7 patients
had MC at time of DLI, and 2 of the 7 converted to CC after
DLI. At last follow-up, only 1 patient in this cohort remained
alive in CR.
DISCUSSION
MRD monitoring has become an integral part of many
protocols for initial chemotherapy of patients with newly
diagnosed ALL [10,12,44], but it is much less frequently
applied after transplantation, where chimerism monitoring
provides an alternative for early relapse prediction. Although
MRD presumably should perform better with regard to this
goal, very limited comparative data actually have been re-
ported, and no reference method has yet been deﬁned
[27,34,45,46].
The present study provides evidence in an adult ALL
population that the higher in vitro sensitivity of MRD testing
and the speciﬁcity for leukemic clones translates directly
into the clinical setting, with earlier detection of imminent
relapse and greater sensitivity and speciﬁcity compared
with chimerism. Owing to low patient numbers, we could
not determine whether such improved detection actuallyresulted in improved outcomes; however, previous studies
indicate that therapeutic intervention at low MRD levels is
advantageous [7,8].
In more detail, our chimerism analysis showed that only
in-MC was associated with increased relapse incidence,
whereas CC, ll-MC, and de-MC had no differential effect on
outcome. These data conﬁrm previous studies in pediatric
ALL [20] and in adult mixed ALL and AML populations [47].
The considerable difference in prognostic impact between
de-MC and in-MC clearly indicates that chimerism is a dy-
namic marker, warranting the analysis of at least 2 time
points before therapeutic interventions are considered. The
dynamic aspect of chimerism also explains why previous
studies that assessed only CC and MC categories and not the
subcategories ll-MC and de-MC failed to identify any prog-
nostic relevance [48,49].
The ﬁnding that ll-MC had no adverse effect on outcomes
compared with CC conﬁrms that stable mixed chimerism at
low levels is compatible with prolonged DFS [20,50], but also
raises the question of whether methodologies for chimerism
assessment with a sensitivity below the 1% to 5% level really
have greater prognostic value in clinical applications. Despite
the fact that various studies have described highly sensitive
detection of potentially malignant cells by conﬁning chime-
rism analysis to the leukemic phenotype [22,27,51], no data
are available indicating that such an approach actually im-
proves relapse prediction [18]. In fact, a recent report by
Zeiser et al. [52] concluded that lineage-speciﬁc chimerism
analysis has no better sensitivity and speciﬁcity for hema-
tologic relapse than the conventional approach, despite a 20-
to 30-fold greater in vitro sensitivity. Likewise, in our study,
chimerism analysis in the CD4þ, CD8þ, and CD19þ sub-
populations had no differential prognostic value, even when
analyzed separately for patients with B-ALL and patients
Figure 2. Cumulative incidence of relapse (A), NRM (B), and OS (C) according
to MRD status in bone marrow in 22 patients undergoing HCT for ALL.
T.H. Terwey et al. / Biol Blood Marrow Transplant 20 (2014) 1522e1529 1527with T-ALL. Thus, it is possible that chimerism monitoring at
1% to 5% sensitivity without selecting for leukocyte subsets is
sufﬁcient for clinical purposes.
With regard to the prognostic value of in-MC status in
bone marrow versus peripheral blood, we found that bone
marrow had somewhat better sensitivity for relapse detec-
tion (79% versus 55%), with a trend for an earlier signal, butlower speciﬁcity (70% versus 87%). Most previous studies
focused on either blood or bone marrow, or did not provide
comparative analyses [20,45,53], and thus this inverse as-
sociation of speciﬁcity and sensitivity of blood and bone
marrow has not been reported previously. A possible ex-
planation for the low speciﬁcity of in-MC in the bonemarrow
is contaminationwith normal stromal cells, which have been
shown to remain entirely of recipient origin after HCT [54],
and can express CD34 [55]. Another possible contributing
factor is that ALL clones can be CD34- at diagnosis [56], or
that CD34 can be lost at relapse [57,58]. In both of these
situations, any CD34 host signal is of purely benign origin,
causing the lower speciﬁcity of this test.
With regard to MRD assessment, our study found that
relapse prediction by MRD was much more sensitive (86%)
and speciﬁc (95%) than prediction by chimerism analysis.
In fact, only 1 of the 22 patients with available MRD data
experienced hematologic relapse without a previous MRD
signal. This patient had been MRD-positive before trans-
plantation, but achieved MRD negativity at day þ28 and
day þ117 while in ll-MC. Because the patient’s chimerism
improved to CC at dayþ251, no further MRDmonitoring was
performed. Stable CC was conﬁrmed at daysþ341 andþ600;
however, at day þ684, the patient experienced hematologic
relapse. The foregoing case, along with our ﬁnding that 31%
of relapses occurred beyond 1 year and that 17% of patients
with CC still experienced relapse, as well as the report from
Rossi et al. [45] of up to 30% MRD positivity in patients with
CC, strongly suggest the importance of continuing MRD
measurements for longer periods even when CC has been
achieved.
MRD positivity after transplantation was associated with
the highest relapse risk of all prognostic groups analyzed,
even when conventional risk factors, such as disease status
at transplantation, or post-transplantation events, such as
occurrence of GVHD, were considered in a multivariate
setting. The median time from ﬁrst MRD detection to relapse
was 173 days, which is in line with previous observations
[30] and indicates an opportunity for timely initiation of
therapeutic interventions [59,60]. In fact, the sole patient
who did not relapse despite MRD positivity was a patient
with Philadelphia chromosome-positive ALL, who was
treated successfully with tyrosine kinase inhibitor therapy.
Importantly, despite the inferior overall performance of
chimerism assessment in our overall analysis and in the
subgroup of patients with available MRD data, 3 of 7 MRD-
positive relapse cases had a chimerism signal even before
MRD, indicating that a combined assessment of these 2
modalities is still useful.
Our data on DLI support previous studies demonstrating
the ability of preemptive and prophylactic DLI to convert
MC to CC, possibly preventing relapse [20,39,61]. Additional
data regarding a protective effect of DLI in ALL also come
from an earlier study demonstrating that DLI-induced GVHD
is associated with a potent graft-versus-leukemia effect [38].
Therapeutic DLI in patients with active disease seems to have
only a limited beneﬁt, however [38,62].
An important limitation of the present study is the po-
tential for bias owing to possible differences in the groups
analyzed. However, with the exception that patients with
available MRD data underwent transplantation more re-
cently and had greater use of ATG compared with patients
without MRD data, all other characteristics were similar,
including the frequency of DLI. Another potential confounder
is that the administration of DLI, affecting the natural history
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application of DLI was included in our multivariate Cox
proportional hazards regression model and was found to
have no signiﬁcant impact on the prognostic value of chi-
merism and MRD assessment. In addition, we applied our
multivariate Cox proportional hazards regression model
separately for patients who recieved DLI and those who did
not, and in that sensitivity analysis, in-MC status and MRD
positivity remained relevant prognostic factors in both pa-
tient cohorts (data not shown). Finally, although the small
number of patients monitored via qPCR for BCR-ABL did not
allow analysis of the relative performance of this assay, and
although some bias might have been introduced because of
the availability of tyrosine kinase inhibitor as a potential
treatment for MRD relapse, we felt that including these
patients was important to maintain the comparability of
patient characteristics in the chimerism and MRD patient
cohorts.
In conclusion, in light of recent advances in therapeutic
options for post-transplantation relapse [7,8,63,64], impro-
ving our understanding of the available relapse prediction
tools is becoming increasingly important. Our study dem-
onstrates the superiority of MRD over chimerism analysis in
this regard, clearly indicating that MRD should be incorpo-
rated into the routine post-transplantation monitoring of all
patients with ALL [11,16,17,23]. Chimerism analysis remains a
valuable tool for monitoring engraftment, especially in the
setting of reduced-intensity conditioning [65], as well as for
patients without a suitable MRD marker [22]. In select cases,
chimerism assessmentmay predict relapse earlier thanMRD,
and it also may be useful for predicting extramedullary re-
lapse, but good clinical judgment accounting for the dynamic
aspects of chimerism is required. Standards for measurement
intervals for MRD and chimerism and deﬁnitions of thresh-
olds for initiating therapy are still missing. Ultimately, pro-
spective studies are needed to determine the optimal use of
these tools with the aim of facilitating risk-adapted thera-
peutic interventions.
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